Hudson Bay Capital Management LP Buys 46,870 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Hudson Bay Capital Management LP increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 22.0% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 260,000 shares of the biotechnology company’s stock after acquiring an additional 46,870 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Arrowhead Pharmaceuticals were worth $4,108,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Arrowhead Pharmaceuticals by 138.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock worth $60,962,000 after acquiring an additional 2,774,933 shares during the period. Marshall Wace LLP grew its stake in Arrowhead Pharmaceuticals by 3,507.8% in the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock worth $34,065,000 after purchasing an additional 2,096,238 shares in the last quarter. Norges Bank purchased a new position in Arrowhead Pharmaceuticals during the 2nd quarter worth $30,414,000. Vanguard Group Inc. raised its position in Arrowhead Pharmaceuticals by 8.4% during the 1st quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock valued at $168,201,000 after purchasing an additional 1,018,273 shares in the last quarter. Finally, Aberdeen Group plc lifted its holdings in shares of Arrowhead Pharmaceuticals by 138.4% in the 1st quarter. Aberdeen Group plc now owns 1,072,827 shares of the biotechnology company’s stock worth $13,668,000 after buying an additional 622,752 shares during the period. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock opened at $68.45 on Tuesday. The business has a fifty day moving average of $46.10 and a 200 day moving average of $29.92. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $9.57 and a 1 year high of $72.36. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86. The firm has a market capitalization of $9.30 billion, a price-to-earnings ratio of -855.52 and a beta of 1.28.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director Michael S. Perry sold 16,250 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $61.03, for a total transaction of $991,737.50. Following the completion of the transaction, the director directly owned 115,240 shares of the company’s stock, valued at approximately $7,033,097.20. This trade represents a 12.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Mauro Ferrari sold 8,750 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $56.39, for a total transaction of $493,412.50. Following the sale, the director owned 68,764 shares of the company’s stock, valued at approximately $3,877,601.96. The trade was a 11.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 45,000 shares of company stock valued at $2,185,150 over the last quarter. 4.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on ARWR. Royal Bank Of Canada upped their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Piper Sandler raised their price objective on Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Bank of America lifted their target price on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Chardan Capital reissued a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, December 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $58.56.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.